Noha E Ibrahim, Mahmoud A W Khader, Mohamed M S Farag, Fatima G Yehia, Amal M El-Feky
{"title":"Gene-virus interaction between IFN-γ rs2069705 polymorphism and Epstein-Barr virus in breast cancer susceptibility among Egyptian women.","authors":"Noha E Ibrahim, Mahmoud A W Khader, Mohamed M S Farag, Fatima G Yehia, Amal M El-Feky","doi":"10.1080/17520363.2026.2716197","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study investigated the association between Epstein-Barr virus (EBV) infection and breast cancer (BC) susceptibility and evaluated the role of interferon-gamma (IFN-γ) rs2069705 polymorphism in disease risk and clinicopathological characteristics among Egyptian women.</p><p><strong>Materials and methods: </strong>A case-control study was conducted on 96 histologically confirmed BC patients and 50 age-matched healthy controls. EBV serostatus was assessed by ELISA detection of anti-viral capsid antigen IgG antibodies. IFN-γ rs2069705 (A/G) genotyping was performed using TaqMan real-time PCR assays.</p><p><strong>Results: </strong>EBV seropositivity was significantly higher in BC patients (93.75%) than controls (<i>p</i> = 0.008). Significant associations were observed between IFN-γ rs2069705 polymorphism and BC susceptibility, particularly for AA and AG genotypes and A and G alleles (<i>p</i> < 0.001), whereas the GG genotype showed no significant association. AA and AG genotypes were also associated with unfavorable clinicopathological features.</p><p><strong>Conclusion: </strong>EBV infection and IFN-γ rs2069705 polymorphism may contribute to BC susceptibility and progression among Egyptian women and could serve as potential combined biomarkers for risk assessment and prognosis.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"673-683"},"PeriodicalIF":2.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13502015/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2716197","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: This study investigated the association between Epstein-Barr virus (EBV) infection and breast cancer (BC) susceptibility and evaluated the role of interferon-gamma (IFN-γ) rs2069705 polymorphism in disease risk and clinicopathological characteristics among Egyptian women.
Materials and methods: A case-control study was conducted on 96 histologically confirmed BC patients and 50 age-matched healthy controls. EBV serostatus was assessed by ELISA detection of anti-viral capsid antigen IgG antibodies. IFN-γ rs2069705 (A/G) genotyping was performed using TaqMan real-time PCR assays.
Results: EBV seropositivity was significantly higher in BC patients (93.75%) than controls (p = 0.008). Significant associations were observed between IFN-γ rs2069705 polymorphism and BC susceptibility, particularly for AA and AG genotypes and A and G alleles (p < 0.001), whereas the GG genotype showed no significant association. AA and AG genotypes were also associated with unfavorable clinicopathological features.
Conclusion: EBV infection and IFN-γ rs2069705 polymorphism may contribute to BC susceptibility and progression among Egyptian women and could serve as potential combined biomarkers for risk assessment and prognosis.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
